Grants & Programs

News & Resources

The Cancer Immunotherapy Consortium embraces communication and collaboration among its members and among other like-minded associations that strive to bring effective immune-based cancer treatments to more patients.

CIC members contribute to the creation of white papers, response documents, and peer-reviewed publications advancing novel outcomes from workshops that seek practical solutions to today's challenges in cancer immunotherapy development.

We invite you to browse our library of publications, news releases, and e-newsletters.

Structured reporting of T cell assay results
Janetzki S, Hoos A, Melief CJM, Odunsi K, Romero P, Britten CM
Cancer Immunity 2013; 13: 13

A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the cancer immunotherapy consortium (CIC/CRI)
McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Odunsi K, Matsuzaki J, Staats JS, Thorpe J, Yuan J, Janetzki S
Cytometry A 2013; Jun 20

The impact of harmonization on ELISPOT assay performance
Janetzki S, Britten CM
Methods Mol Biol 2012 ;792: 25-36

Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring
Hoos A, Janetzki S, Britten CM
Oncoimmunology 2012; 1: 1457-1459.

T cell assays and MIATA: the essential minimum for maximum impact
Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM
Immunity 2012; 37: 1-2

The immuno-oncology framework: Enabling a new era of cancer therapy
Hoos A, Britten C
Oncoimmunology 2012; 1: 334-339

A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols
Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, Clay T, Yuan J, Odunsi K, Hoos A, Romero P, Britten CM; CRI-CIC Assay Working Group
J Transl Med 2011; 9: 108

Harmonization of immune biomarker assays for clinical studies
van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A
Sci Transl Med 2011; 3: 108ps44

A methodological framework to enhance the clinical success of cancer immunotherapy
Hoos A, Britten CM, Huber C, O'Donnell-Tormey J
Nat Biotechnol 2011; 29: 867-870

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond
Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM
Cancer Immunol Immunother 2011; 60: 15-22

Improved endpoints for cancer immunotherapy trials
Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J
J Natl Cancer Inst 2010; 102:1388-97

Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells
Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A
Cancer Immunol Immunother 2010; 59: 609-18

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS
Clin Cancer Res 2009; 15: 7412-20

"MIATA"-minimal information about T cell assays
Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM
Immunity 2009; 16; 31: 527-8

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium
Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, Odunsi K, Pride M, Old L, Hoos A, Romero P; HLA-peptide Multimer Proficiency Panel of the CVC-CRI Immune Assay Working Group
Cancer Immunol Immunother 2009; 58: 1701-13

Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC)
Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A
Vaccine 2007; 25 Suppl 2: B97-B109. Review

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)
Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A; Elispot Proficiency Panel of the CVC Immune Assay Working Group
Cancer Immunol Immunother 2008; 57: 303-15

Toward the harmonization of immune monitoring in clinical trials: quo vadis?
Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A
Cancer Immunol Immunother 2008; 57: 285-8

A clinical development paradigm for cancer vaccines and related biologics
Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G; Cancer Vaccine Clinical Trial Working Group
J Immunother 2007; 30: 1-15. Review

Publications prior to 2010 are credited to the Cancer Vaccine Consortium, the former name of the Cancer Immunotherapy Consortium

Become a member

Are you interested in becoming part of the Cancer Immunotherapy Consortium?

Join Now

Contact Us

Want to learn more about the Cancer Immunotherapy Consortium? Contact a CIC representative at consortium@cancerresearch.org or (212) 688-7515.